Mayo Clinic researchers have developed a new way to predict whether existing drugs could be repurposed to treat heart failure ...

A majority of cancer drugs approved in the US during 2019-2022 had “clinical trial uncertainties,” research suggests.

The CORE-MD (Coordinating Research and Evidence for high-risk Medical Devices) consortium has published new consensus ...

ShiraTronics, Inc., a clinical-stage medical device company focused on developing novel neuromodulation therapies for chronic ...

Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1 Filing ...

A microsimulation model was used to evaluate the cost-effectiveness of two glucagon-like peptide-1 receptor agonists (GLP1RAs), semaglutide and tirzepatide, for patients with osteoarthritis and ...

According to ESC, these recommendations respond directly to a request from the European Commission to provide expert advice ...

Recently initiated Phase 1b/2 multiple ascending dose study intended to assess safety and efficacy in nAMD patients receiving four initial ...

TPD technologies, particularly PROTACs and MGDs, represent a paradigm shift in drug development by completely eliminating ...

Design We conducted a prospective, non-randomised cohort study on a cohort of abdominal or pelvic cancer patients who developed ... Results WMT significantly alleviated multiple clinical symptoms in ...